Background. CNS 7056 is an esterase-metabolized benzodiazepine sedative currently under development. Its short duration of action would suggest a clinical role similar to midazolam or propofol.
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A recent dose-escalation study of CNS 7056 in sheep showed that doses in the range 0.37 -2.21 mg kg 21 (given as a 2 min infusion) produced sedation with loss of consciousness (LOC) for 9 -25 min. 2 As a short-acting sedative/anaesthetic, the potential clinical roles of CNS 7056 would be similar to those of midazolam and propofol. It is therefore of interest to compare the sedative qualities of CNS 7056 with these established agents. Important properties include the relative depth and duration of sedation/anaesthesia, the relative depression of the respiratory system, and the relative depression of the cardiovascular system. Ideally, a range of doses of each agent should be studied, so that the sedative properties can be compared at near equi-anaesthetic doses. Therefore, the aim of this study was to compare sedation with low, medium, and high doses of CNS 7056 with low, medium, and high doses of its comparator drugs midazolam and propofol using a conscious chronically instrumented sheep preparation.
General methods for sheep preparation
The general methods for the sheep preparation have been described in detail previously. 2 In brief, female Merino sheep aged 1 -3 yr were prepared surgically with instrumentation for blood sampling and physiological measurements. Each sheep was prepared with: two aortic catheters (for blood sampling and arterial pressure), one pulmonary artery thermodilution catheter [for blood sampling and cardiac output (CO) measurement], one sagittal sinus catheter (to sample effluent blood from the brain), and three catheters outside the right atrium (for central venous pressure, CO injectate, and drug administration). A Doppler flow probe was secured above the dorsal sagittal sinus [for measuring an index of cerebral blood flow (CBF)] 3 4 via a trephine hole. For EEG measurements, two silver electrodes were placed under the skull but above the dura on either side of the trephine hole, and a reference electrode was placed under the scalp.
Experiments commenced 2 days after surgery. Sheep were trained to walk from their pen into a mobile experimental crate, and for each experiment, the sheep in its crate was rolled into a quiet study room isolated from other sheep. The sheep were placed in a weight-bearing sling inside the crate that supported the sheep with the onset of sedation or anaesthesia. Sheep breathed room air with unassisted ventilation during the studies.
Compounds
CNS 7056 [4H-imidazol[1,2-a] [1, 4] benzodiazepine-4-propionic acid, 8-bromo-1-methyl-6-(2-pyridinyl)-(4S)-methyl ester, benzenesulphonate (1:1)] was supplied as a powder by Paion UK Limited (Cambridge, UK). On each experimental day, an appropriate quantity of CNS 7056 was dissolved in saline 0.9% and sterilized by passage through a 0.22 mm filter (Millex GP, Millipore, Ireland). Midazolam (5 mg ml 21 ) was either Sandoz Batch no. 05D22FAA or Pfizer Batch no. CB43. Propofol (10 mg ml 21 ) was either Mayne Pharma Cat. no. 00142B Batch no. 05E330 or Pharmatel Fresenius Kabi Pty Ltd Batch no. UF164.
Experimental studies
For each instrumented sheep, CNS 7056 was studied first. Each sheep was administered doses of 0.37, 0.74, and 1.47 mg kg 21 CNS 7056 base infused i.v. over 2 min on consecutive days and in alternating order (e.g. high dose first or high dose last). These sheep had blood samples obtained for pharmacokinetic analysis (to be reported elsewhere). Two days after the last dose of CNS 7056, the sheep were assigned to receive either midazolam or propofol in alternating order. Midazolam was administered at doses of 0.05, 0.1, and 0.2 mg kg 21 infused i.v. over 2 min on consecutive days and in alternating order (e.g. high dose first or high dose last). Propofol was administered at doses of 1, 2, and 4 mg kg
21
, also on consecutive days and in alternating order (e.g. high dose first or high dose last). Additional sheep that did not receive CNS 7056 were also prepared once the CNS 7056 study series was finished as necessary to achieve a total of six studies per dose of each comparator drug. In three sheep, additional very high doses of midazolam (0.4 mg kg
) were given to determine if there was a ceiling level of sedation for this drug. A summary of the doses used and total sheep numbers is provided in Table 1 . Drugs and doses were administered in alternating rather than random order to ensure that the groups were of balanced sizes, as the total number of studies possible was contingent on the availability of test compound. This also allowed the order of the doses and drugs to be tested in a structured manner.
In all experiments, the following pharmacodynamic measures were made for 5 min before the drug, and after the administration of the drug until EEG readings had returned to baseline for at least 10 min.
Sedative effects
The EEG was recorded using a Datex-Ohmeda S/5 monitor. The Entropy module of this monitor was used to record the state entropy (SE) and response entropy (RE) 5 at 5 s intervals as described previously. 2 The S/5 monitor was also used to record the raw EEG waveforms at a sampling rate of 400 Hz for later off-line analysis. The power spectrum of 8 s EEG epochs was calculated using the fast Fourier transform (FFT) and used to calculate the average power in the a frequency band (8 -13 Hz). Loess smoothing functions were used for reduction and pooling of the EEG data. The a power has previously been shown to be a reliable continuous measure of sedation for CNS 7056 in the sheep over a large range of doses. 2 Images of the head and front of the sheep were recorded during the studies using a digital video camera and stored on DVD for later analysis. The video was reviewed by one observer. As in our earlier work, 2 LOC for the three measures of sedation were defined as follows: (i) for SE/RE: by breaks in the baseline values of the readings; (ii) for a power: by readings above the 95% confidence intervals of baseline; and (iii) for video analysis: by inability of the sheep to hold its head up. Often the head would drift down slowly during the onset of sedation. The start of LOC was taken to be when the head was at its nadir. During LOC, the head was generally motionless except for manual handling and respiratory movement. On recovery, it was common for the sheep to suddenly lift their heads, which was taken as the end of the period of LOC.
Respiratory effects
The inlet tube of a capnograph (Datex Cardiocap) was placed at a nostril of each sheep to sample inspired and expired air. The analogue output of the capnograph ( per cent CO 2 ) was collected digitally at a sample rate of 50 Hz. The resultant data file was analysed off-line to calculate the ventilatory frequency at 1 min intervals. Before each study, the capnograph was tested by comparison with a reference gas (CO 2 5.19%, balance air).
Arterial blood and sagittal sinus gas samples were obtained at 0 (baseline), 2, 5, 10, and 20 min after the start of the drug infusions in all studies. The samples were sealed in air-tight heparinized syringes and stored in ice for later analysis using an Osmetech OPTI blood gas analyser.
Cardiovascular effects
Calibrated arterial pressure transducers were connected to an arterial and a central venous catheter of each sheep to measure mean arterial pressure (MAP) and central venous pressure (CVP), respectively. The analogue pressure waveforms were recorded digitally at a sampling frequency of 50 Hz. An index of CBF was recorded from the output of the ultrasonic Doppler crystal on the sagittal sinus, 3 4 also at a sampling frequency of 50 Hz. CO was measured using a thermodilution method and the thermistor-tipped pulmonary artery catheter. Measurements were made in triplicate with injections of 10 ml of ice-cold saline at 0 (baseline), 2, 5, and 10 min, and 10 minutely thereafter for the midazolam and propofol studies. Measurements were not made at 2 and 5 min for the pharmacokinetic studies of CNS 7056 for logistical reasons, but measurements were made at these times in earlier studies. 2 The CO at a particular time was taken as the mean of the three readings. Core body temperature was recorded concurrently with CO via the thermodilution catheter.
The time-courses of MAP, CVP, and CBF at 1 min intervals were derived by fitting a loess smoothing function to the data, after manually removing artifacts due to disconnections or movement. A separate analysis recorded the lowest MAP in the 5 min period after the start of the drug infusion.
Statistical analysis
Linear mixed effect models were used as a general tool for statistical analysis because of their ability to account for within-and between-animal variability (i.e. repeated measures), and ability to cope with unbalanced data. 6 7 Data with multiple measurements in the baseline period (EEG, arterial and venous pressures, ventilatory frequency, heart rate, and CBF) were analysed for each dose group using a linear mixed effect model. 'Sheep' was the random grouping factor, and the model compared the observed values of the variable in the baseline period (25 to 0 min) and the values of the variable in the 2 min period following the drug that centred around the time of the peak drug effect (e.g. 1-3 min). The key outputs from this analysis were the mean of the observed variable in the baseline period and its standard error (SE), the change (D) in the variable for the drug period and its SE, and the P-value for the change for each dose. The change in the variable with the drug was also expressed as a percentage of baseline for convenience.
Data that were measured only once in the baseline period (CO and blood gas measurements) were analysed using a similar approach to that described above, but with a comparison of the variable for time¼0 min (baseline) and the single post-drug time point representing the peak drug effect (drug).
The relationship between two variables across all studies was examined using standard linear regression, with a relationship declared significant, if the slope term was statistically different from zero.
The significance level was P¼0.05 unless indicated otherwise. All data were analysed using the 'R' data analysis software, Version 2.4.1. 8 
Results

Sedative effects
The duration of LOC by the three indices of sedation (SE/ RE trace, EEG a power, and video analysis) is summarized in Table 2 . The smoothed time-courses of the EEG a power are shown in Figure 1 for CNS 7056, Figure 2 for midazolam, and Figure 3 for propofol. The peak a power was statistically significant from baseline for all doses of CNS 7056, the medium and high doses of propofol, and the high dose of midazolam (Table 3) .
For all three doses of CNS 7056, there was a good agreement in the duration of LOC by the three sedation indices. This was facilitated by the clear transition between the conscious and the unconscious, motionless state for this drug, which was very evident during the video analysis. The low, medium, and high dose ranges all produced LOC, with average durations of 12, 15, and 20 min. CNS 7056 was characterized by rapid onset and offset of sedation, with the duration, rather than magnitude, of sedation increasing with the dose. The sedation was relatively deep for all three doses (Table 3) .
By comparison with CNS 7056, the sedation produced by midazolam was not as deep and was highly dosedependent (Table 1 ; Fig. 2 ). The lowest dose of midazolam produced no LOC, but transient drowsiness was evident in all sheep. The high dose of midazolam produced LOC for 20 min, but the quality of the sedation was low, with some sheep showing movement and transitions into and out of consciousness during the overall LOC period. This is consistent with Figure 2 , which shows that the EEG a power returned slowly to baseline over an extended period. Although the high dose of midazolam produced a mean duration of sedation that was similar to that produced by the highest dose of CNS 7056, the overall depth of the sedation was less ( peak a power of 4 vs 12 mV 2 ). Furthermore, the rate of onset, and particularly offset, of sedation was slower. Thus, in the 'recovery' phase, the underlying level of midazolam-induced sedation changed relatively slowly, with long periods in the region that was neither asleep nor awake. In this state, the sheep were evidently arousable by environmental stimuli. As the ). While there was an increase in the a power (Fig. 2) and doubling the dose approximately doubled the a power, this was associated with a very long, slow recovery from sedation (40 min to return to baseline). Thus, the slow recovery from the effects of midazolam seemed to be an intrinsic property of this drug that could not be overcome by increasing the dose.
By comparison with CNS 7056, the sedation produced by propofol was nearly as deep, but the depth was more dose-dependent (Table 2 ; Fig. 3 ). The lowest dose range of propofol was not associated with LOC, but produced drowsiness. The high dose of propofol produced a duration of sedation that was less than that for the other two drugs (16 min). However, the depth of sedation by the a power for the high dose was comparable with that achieved with CNS 7056 (10 vs 12 mV 2 ). Propofol was in general characterized by relatively slow and variable onset for this 2 min infusion paradigm, with some sheep requiring up to 5 min before LOC. Indeed, for the high-dose range, individual sheep sometimes showed a rapid onset of sedation, a slight recovery, and then re-sedation (apparent in individual data). In contrast, the rate of recovery from sedation for propofol was generally rapid.
Respiratory effects
Ventilatory frequency data were expressed as a per cent of baseline to account for sheep-by-sheep variation in baseline ventilatory frequency. All three drugs produced comparable reductions in normalized ventilatory frequency for the higher doses ( Table 4 ). The reductions in ventilatory frequency were associated with transient increases in arterial carbon dioxide tension, which was more pronounced for CNS 7056 and propofol than midazolam (Table 5) . A concurrent mild but statistically significant respiratory acidosis was also evident [for the high-dose groups, the maximum change in pH was 20.04 units (P,0.01) for CNS 7056, 20.05 units (P,0.01) for midazolam, and 20.05 units (P,0.01) for propofol]. There were noticeable decreases in arterial oxygen tension for all doses of CNS 7056 and propofol (Table 6) , and these were also associated with minor transient haemoglobin desaturation that was statistically significant for CNS 7056 and propofol only [for the high-dose groups, the maximum change in saturation was 25.6% (P,0.01) for CNS 7056, 20.2% (P¼0.64) for midazolam, and 26.4% (P,0.01) for propofol]. The decreases in oxygen tension and saturation were exacerbated by the fact that the sheep were breathing room air, but the desaturation was not of sufficient extent or duration to endanger the animals. Respiratory depression is generally a consequence of depressing the brainstem, and it could be postulated that the greater the depression of the brain (i.e. the greater the sedation), the greater the associated respiratory depression regardless of the drug causing the sedation. This hypothesis was tested in Figure 4 , which shows that across all three drugs, the magnitude of the respiratory depression observed (via oxygen tension) was in general terms proportionally related to the depth of anaesthesia obtained (via EEG a power). Arterial oxygen tension is one of the more sensitive measures of respiratory depression in this experimental preparation, as it is a physiological variable that is not subject to homeostatic compensation in the ranges of values achieved. Figure 4 shows that CNS 7056 produced respiratory depression consistent with the level of sedation achieved-that is, the greater depression observed for CNS 7056 over midazolam and lower doses of propofol was largely because, at the doses used, it was a more powerful sedative.
Cardiovascular effects
All three drugs caused mild, transient but statistically significant hypotension (Table 7) . However, the above analysis used MAP pooled over 1 min intervals which may underestimate the transient decrease in MAP. A second analysis was conducted to find the lowest MAP recorded in the 10 min after the start of the drug infusions. These Table 3 Statistical summary comparing the effect of CNS 7056, midazolam, and propofol on maximum EEG a power. The table shows the EEG a power (a) in the baseline period (25 to 0 min), and the maximum change in a power (Da) with the drug. The per cent change in a power and the time of the maximum a power are also shown. and propofol, and 55 mm Hg for midazolam. These pressures were high enough to ensure perfusion of vital organs. All three drugs also caused sustained, statistically significant reductions in central venous pressure (Table 8) , probably reflecting drug-induced vasodilatation. Hypotension and vasodilatation were partly compensated for by substantial increases in heart rate, which was statistically significant for all drug groups but the lowest dose of midazolam ( . This change for CNS 7056 might reflect a reduction in peripheral (e.g. skeletal muscle) perfusion rather than vital organ perfusion, as the sheep receiving CNS 7056 were noticeably more motionless than for the two other drugs.
CBF was decreased to similar extents by CNS 7056 and the higher doses of propofol, but not by midazolam (Table 10 ). This is a feature of most i.v. anaesthetics that reduce cerebral oxygen demand with intact flowmetabolism coupling. The greater effects of CNS 7056 and propofol are compatible with the greater anaesthesia and hence greater cerebral depression for these drugs. There were minimal changes in sagittal sinus oxygen tension for all three drugs, suggesting that any reductions in CBF were due to reduced cerebral oxygen demand rather than cerebral vasoconstriction (i.e. further evidence that flow-metabolism coupling was maintained). For the high-dose groups, the maximum change in sagittal sinus oxygen tension was þ2.0 mm Hg (P¼0.27) for CNS 7056, þ2.8 mm Hg (P¼0.72) for midazolam, and þ2.7 mm Hg (P¼0.52) for propofol.
Baseline core body temperature was in the normal range for these experiments, but for all doses of all drugs, there was a significant reduction in temperature after drug administration [for the high-dose groups, the maximum change in temperature was 20.508C (P,0.01) for CNS 7056, 20.428C (P,0.01) for midazolam, and 20.548C (P,0.01) for propofol]. This might reflect heat loss due to vasodilatation, as this also occurred for all doses of all drugs, as reflected by reductions in central venous pressure (Table 8) .
As for the analysis of respiratory depression above, it could also be postulated that the greater the depth of anaesthesia, the greater the associated cardiovascular depression regardless of the drug causing the sedation. This hypothesis was tested for MAP in Figure 5 , where the changes in MAP were plotted against the changes in EEG a power for all doses of all drugs. A relationship is evident, but the slope was not statistically significant. This relationship was also reflected in the analogous plot for heart rate (Fig. 6) , which was statistically significant. It could be argued that, in this experimental paradigm, heart rate is a sensitive measure of the underlying drug-induced This graph shows the relationship between the maximum change in the a power of the EEG (reflecting the depth of anaesthesia) and the change in arterial oxygen tension (Pa O 2 ) at 2 min, reflecting the magnitude of respiratory depression. Each symbol is the mean of one dose group for the drugs shown. The R 2 value of the line of best fit was 0.78, the slope was [mean (SE)] 22.37 (0.45) (P,0.01). The non-zero slope of the line supports the general hypothesis that (regardless of the drug) the greater the anaesthesia, the greater the respiratory depression. cardiovascular depression, as it represents the extent to which the body reacts to maintain homeostasis. Therefore, as was the case for respiratory depression, the data show that CNS 7056 produced cardiovascular depression consistent with the level of sedation achieved, and that the greater depression observed for CNS 7056 over midazolam and the lower doses of propofol was largely because it was a more powerful sedative at the studied dose levels.
Discussion
When comparing anaesthetics and sedatives, it is important to compare equi-anaesthetic doses if possible. However, the quality of sedation is multi-dimensional with influences of both duration and depth. In this study, the reference point chosen was the duration of sedation, with an attempt to produce 20 min of sedation for the high-dose groups for each drug, with the medium-and low-dose groups being two-and four-fold reductions in dose, respectively. This aim was achieved in general terms.
It is clear that CNS 7056 produced substantial sedation with rapid onset and offset over a wide dose range. In comparison, midazolam produced less sedation, had a slower recovery, and produced varying responses across the dose range used. Thus, lower doses had minimal effect, while increasing the dose produced long-term sedation. This behaviour in sheep matches anecdotal reports of the behaviour of midazolam in man.
It is often not appreciated that propofol has a relatively slow onset of effect in both sheep 9 and man. 10 A rapid onset of effect is sometimes achieved clinically by means of high doses injected rapidly with consequent hypotension. 11 In this study, where a 2 min infusion was used, propofol had a relatively slow rate of onset compared with CNS 7056. The depth of sedation produced by both drugs was comparable for the medium and high doses, but propofol was more sensitive to dose reductions than CNS 7056, in that the low dose produced a relatively lower depth of sedation.
All three drugs produced dose-dependent respiratory depression, reductions in MAP and central venous pressure, and increases in heart rate. The magnitude of these changes was broadly proportional to the depth of anaesthesia achieved for any given drug or dose. For all three drugs, the respiratory and cardiovascular depression was not of sufficient magnitude to endanger the animals. When considering the respiratory and cardiovascular effects of the high doses, it is apparent that midazolam 0.2 mg kg 21 had minimal impact on these physiological systems. This is consistent with the lower depth of sedation produced by this dose of midazolam compared with the other drugs. A higher dose of midazolam (0.4 mg kg 21 ) was also examined in three animals. Deeper sedation and more profound effects on the cardiovascular and respiratory system were observed using this dose. The high doses of CNS 7056 and propofol both caused transient respiratory and cardiovascular depression, of similar duration and magnitude. The change in CO was small, suggesting no major circulatory disturbance. The depression of CBF produced by CNS 7056 and propofol was likely consistent with them causing a general depression of neuronal activity and cerebral oxygen consumption. In general, the pattern of respiratory and cardiovascular effects seen for CNS 7056 and propofol is consistent with that expected for drugs that are general central nervous system depressants. It should be noted that in this experimental paradigm, some of the depressant effects on the cardiovascular system would be masked by the stimulatory effects of evolving hypercapnia. Conversely, the use of 2 min infusion rather than a rapid bolus will tend to reduce the peak cardiovascular effects. 11 It is concluded that CNS 7056 had advantages over midazolam (more rapid offset and greater depth of sedation), and some advantages over propofol (more rapid onset and less dose-dependency of depth of sedation). The cardiovascular and respiratory effects of CNS 7056 were consistent with the level of sedation it produced. It is of Although not statistically significant, trend in the data supports the general hypothesis that (regardless of the drug) the greater the anaesthesia, the greater the cardiovascular depression. Change in heart rate vs depth of anaesthesia. This graph shows the relationship between the maximum change in the a power of the EEG (reflecting the depth of anaesthesia) and the maximum change in heart rate, reflecting the magnitude of cardiovascular depression. Each symbol is the mean of one dose group for the drugs shown. The R 2 value of the line of best fit was 0.75, the slope was [mean (SE)] 3.37 (0.68) (P,0.01). The non-zero slope of the line supports the general hypothesis that (regardless of the drug) the greater the anaesthesia, the greater the cardiovascular depression. great interest to determine if these desirable properties of CNS 7056 are also evident in man.
